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Stem/stromal cell-based therapies are a branch of regenerative medicine and stand as an attractive option to promote the repair of 
damaged or dysfunctional tissues and organs. Olfactory mucosa mesenchymal stem/stromal cells have been regarded as a promising 
tool in regenerative therapies because of their several favorable properties such as multipotency, high proliferation rate, helpful 
location, and few associated ethical issues. ese cells are easily accessible in the nasal cavity of most mammals, including the rat, 
can be easily applied in autologous treatments, and do not cope with most of the obstacles associated with the use of other stem 
cells. Despite this, its application in preclinical trials and in both human and animal patients is still limited because of the small 
number of studies performed so far and to the nonexistence of a standard and unambiguous protocol for collection, isolation, and 
therapeutic application. In the present work a validation of a protocol for isolation, culture, expansion, freezing, and thawing of 
olfactory mucosa mesenchymal stem/stromal cells was performed, applied to the rat model, as well as a biological characterization 
of these cells. To investigate the therapeutic potential of OM-MSCs and their eventual safe application in preclinical trials, the main 
characteristics of OMSC stemness were addressed.
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1. Introduction
In the last decades, cell-based therapies have stood out in the 
medical and research fields, appearing as an alternative to the 
treatment of several diseases and pathologies previously diffi-
cult to approach [1]. e application of these therapies is based 
on the repair of the mechanisms associated with the begin-
ning, establishment, or progression of the disease. rough 
trophic effects or native cell replacement [2], cell therapies use 
stem/stromal cells to promote their differentiation in specific 
locations and under intended pathological conditions [3]. 
Stem/stromal cells are classified as undifferentiated, capable 
of proliferating indefinitely under proper conditions and able 
to differentiate into cell types and tissues depending on the 
stimulus received. Over the years, the search for readily avail-
able, safe, stable, and potentially effective stem/stromal cells 
for regular use in regenerative medicine has been intense [4]. 
ese characteristics were initially identified in cells isolated 
from the mouse bone marrow, which exhibited desirable char-
acteristics such as plastic adhesion and modification into fibro-
blastic colony units under culture [5]. Developing from the 
mesoderm and with ability to differentiate into specialized 
cells, these cells were later named as mesenchymal stem/stro-
mal cells (MSCs). Also known as multipotent cells, MSCs are 
heterogenic stromal cells that have already been identified and 
can be collected in virtually all adult tissues of several species. 
Able to self-renewing, multipotent, almost always easily acces-
sible, expandable in vitro cultures and exceptionally stable 
from a genetic point of view, they are a fundamental focus of 
regenerative medicine and tissue repair [6, 7]. e application 
of MSCs in regenerative medicine deals with special charac-
teristics such as their easy expansion in culture, ability to dif-
ferentiate into the desired cell types, specific immunological 
characteristics (immune-privileged and immune-modula-
tion), tropisms for lesion sites, trophic stimulation capacity, 
and also modulation of tissue functions and inflammation by 
secreting important bioactive molecules [8]. In contrast to 
other therapeutic approaches where a complete and unequiv-
ocal characterization of the mechanisms of action are stab-
lished before its use, in the case of MSCs, its therapeutic 
advantages have already been broadly characterized even if 
there is not yet a complete understanding of its way of action 
or in vivo function [7].
Since its first description, MSCs have already been iden-
tified in several adult tissues, with very few exceptions. Tissues 
where they have been identified include adipose tissue, amni-
otic fluid, amniotic membrane, sub-amniotic umbilical cord 
lining membrane, Wharton’s jelly, endometrium, menstrual 
blood, peripheral blood, placenta and fetal membrane, dental 
pulp, salivary glands, skin and foreskin, synovial membrane 
and olfactory mucosa (OM) [4, 9].
Despite its use and regular characterization, there is no 
universal definition or conclusive assays that allow the unam-
biguous identification of MSCs in a mixed population of cells 
[6]. In 2006, the International Society for Cellular erapy 
(ISCT) focused on creating a more specific definition of MSCs 
and establishing minimum criteria for their identification. 
ese cells must: (a) be plastic-adherent under standard cul-
ture conditions; (b) present a set of markers (differentiation 
clusters) including CD73, CD90, CD105 absence of CD14, 
major histocompatibility complex- (MHC-) II/human leuko-
cyte antigen- (HLA-) DR and markers for hematopoietic lin-
eage such as CD34, CD45; and (c) be able to differentiate in 
vitro in at least three cell lines: adipogenic, chondrogenic, and 
osteogenic [10]. ese characteristics are well-defined for 
human MSCs, even if slight differences in MSCs isolated from 
distinct tissues can be identified. Nevertheless, these criteria 
may not be adequate to characterize MSCs for all species. 
Commonly used antibodies do not recognize the analogous 
surface antigens of animal cells with the same affinity, and 
variations in expression levels thereof may occur as compared 
to the manifestations in human cells [11]. However, the criteria 
defined for humans are still those used for the characterization 
of animal cells and should be used in an adapted and weighted 
manner. Concerning the capacity for differentiation, multiple 
studies carried out have made it possible to perceive that MSCs 
are capable not only of traditional tridifferentiation but also 
of originating other cells and tissues with mesodermal (liga-
ments, tendons, cardiomyocytes, muscles), ectodermal and 
endodermal origin (skin, retina, lungs, hepatocytes, renal 
tubes, pancreatic islets, sebaceous glands and ducts and neural 
cells) [12]. Also, recently new markers have been explored to 
identify those that can be considered stemness-associated 
MSC stromal cell markers, in opposition to the traditional 
MSC markers that some authors question and indicate as more 
appropriate to be considered stromal cell markers [13]. In this 
group, CD271 is indicated as a potential precursor for homo-
geneous subpopulations of MSCs and described as a way to 
improve culture homogeneity. Even so, some studies show that 
even CD271-MSCs are heterogeneous in their proliferative, 
differentiation and immunomodulatory potential, contribut-
ing to the heterogeneous adult MSC properties [14]. us, the 
identification of new functionally relevant surface markers is 
important to ensure the creation of robust quality criteria that 
will allow better control in the use of MSCs.
MSCs collected at the lamina propria of OM are named 
olfactory mucosa mesenchymal stem/stromal cells (OM-MSCs) 
and although the elements of the olfactory system originate 
from an interaction between ectoderm-derived placodes and 
migrating cranial neural crest cells [15] lamina propria compo-
nents and therefore OM-MSCs are thought to be largely derived 
from the neural crest [16]. OM-MSCs were initially identified 
in the OM of an embryonic rat [17]. e different studies already 
carried out for its characterization allowed to identify its capac-
ity to form fibroblastic-like low density colonies and the expres-
sion of classic markers and those related to differentiation [15]. 
Although able to tridifferentiate, OM-MSCs seem to differen-
tiate more easily into osteoblasts than into chondroblasts and 
adipocytes [15]. In addition, they can still follow a myogenic 
and neurogenic differentiation [18] and its conditioned medium 
promotes the proliferation of ensheathing cells, oligodendrocyte 
precursor cells and myelination in vitro [18, 19]. e most 
important characteristics that make these cells optimal candi-
dates for regenerative medicine are its high versatility, wide 
distribution in nasal cavity [20], easy access with few associated 
ethical issues and little susceptibility to the development of chro-
mosomal or tumorigenic alterations [21, 22]. Even with high 
mitotic activity, these cells can maintain self-renewal ability in 
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culture for long periods of time by conserving telomeric activity 
and inhibiting apoptotic activity, characteristics that are not 
affected by the donor’s age [23].
e anatomical location of the olfactory mucosa is excel-
lent for both antemortem and postmortem collection in most 
species of clinical interest. OM harvesting in small animal 
models, such as rat, mouse, or rabbit, requires euthanasia, but 
the peripheral location of the tissue and use of appropriate 
aseptic techniques during collection allow to reuse animals 
from other studies, once there is a guarantee that no contam-
ination of the olfactory region occurred [17, 24–26]. An ante-
mortem collection method for rats have also been described, 
but its complexity makes it harder to be applied regularly to 
collect OM and isolate OM-MSCs [24, 27] In humans and 
larger species, OM can be easily collected in vivo using rhi-
noscopy techniques and nasal forceps [15, 28–30], then mak-
ing OM-MSCs great candidates for autologous transplantation 
in domestic animals and humans to treat different types of 
lesions, specifically nerve damages.
Previous studies on OM-MSCs’ secretome allowed to iden-
tify the production and secretion of bioactive molecules with 
a direct influence on neural differentiation, namely in the pro-
duction and maturation of glial cells [31]. In addition, its clin-
ical potential has already been tested in the field of experimental 
neurology, as in the treatment of neurodegenerative diseases 
of the central nervous system [32], hippocampal lesions [33, 
34], in the regeneration of the peripheral nerves and cranial 
nerves [35–38] and in cases of spinal cord trauma [39, 40]. Its 
immune-suppressive effect over autoimmune diseases [41, 42] 
and regenerative promotion in myocardial tissue aer infarct 
[43] and ischemic tissues [44] was also evaluated.
So far, OM-MSCs have been studied and characterized in 
different extents in species such as humans [15], mouse [45], 
rabbit [26], dog [28], sheep, horse, macaque, and lemur [29]. 
Rat’s OM-MSCs, an animal model with a particular interest 
in regenerative medicine of the nervous system and peripheral 
nerve, have already been explored in some studies [17, 27, 29], 
although there is still much to discover and study about 
OM-MSCs in this species.
e aim of this work was to perform a complete charac-
terization of rat’s OM-MSCs, using a complete, longitudinal, 
and sequential approach not observed in other studies. Special 
emphasis was given to the methods of cell isolation, culture 
and expansion, freezing and thawing protocols. Moreover, its 
biological characterization was carried out in relation to cell 
behavior in culture, determination of cellular karyotype, deter-
mination of cell genetic expression, identification of specific 
proteins from the cell surface, testing of multilineage differ-
entiation capacity and characterization of the secretome pro-
file during expansion, regarding immune-modulatory capacity. 
Envisioning their subsequent use in regenerative therapies, 
the OM-MSC stemness characteristics were also evaluated.
2. Materials and Methods
All procedures performed on animals were approved by the 
Organism Responsible for Animal Welfare (ORBEA) of the Abel 
Salazar Institute for Biomedical Sciences (ICBAS) from the 
University of Porto (UP) (project 209/2017) and by the Veterinary 
Authorities of Portugal (DGAV) (project DGAV: 2018-07-11 
014510). All animal testing procedures were in conformity with 
the Directive 2010/63/EU of the European Parliament and the 
Portuguese DL 113/2013, and followed in accordance to the 
OECD Guidance Document on the Recognition, Assessment 
and Use of Clinical Signs as Humane Endpoints for Experimental 
Animals Used in Safety Evaluation (2000). Adequate measures 
were taken to minimize pain and discomfort considering 
humane endpoints for animal suffering and distress.
Ten Rats (Rattus norvegicus), Sprague Dawley, male gen-
der, with 8-9 weeks of age and 200–300 g BW were used for 
the collection of the OM tissue. In a 3 R’s perspective, and in 
collaboration with other works within the research group, 
animals considered for tissue collection were reused, as they 
were sacrificed for other research purposes. Animals were 
preanesthetized with xylazine (Rompun®, 1.25 mg/g) and 
Ketamine (Imalgene 1000®, 9 mg/100 g) intraperitoneally in a 
single administration. Euthanasia was performed using a 
chemical method of anesthetic overdosing with pentobarbital 
sodium (Eutasil® 200 mg/ml injectable solution, Ceva Santé 
Animale, 200 mg/kg) administered intraperitoneally.
2.1. Collection of Olfactory Mucosa. OM was collected as 
previously described [24]. e collection itself was made 
using a tweezer, and atraumatically, the OM lining the 
olfactory recess, regions of the nasal septum and remnant 
ethmoturbinates was detached and immediately immersed 
in transport medium consisting on phosphate-buffered 
saline solution (PBS) (DPBS, Sigma-Aldrich®). A needle was 
used to gently peel the mucosa from the tip of the tweezers 
for deposition into the solution. OM pooled samples from 
different animals was collected and conditioned at 4–6°C.
2.2. Sample Transport and Storage. Once the collection of 
OM was completed, the fragments were transported in the 
transport medium to the laboratory facilities as soon as 
possible under refrigerated temperatures of 4°C–6°C. Here, 
whenever immediate processing was not possible, fragments 
of OM were centrifuged within the transport medium, with 
subsequent removal of the supernatant. e fragments 
were then resuspended in a storage solution comprising 3% 
antibiotics [penicillin 100 U/mL/streptomycin 100 μg/mL) 
(Sigma-Aldrich®)], 3% antimycotic [amphotericin B (2.5 μg/
mL) (Sigma-Aldrich®)] and PBS. Aer this procedure, the 
fragments were stored overnight with the storage solution at 
a refrigeration temperature of 4°C–6°C or cryopreserved for 
later use. To ensure integrity, the time between this storage and 
the processing of the samples never exceeded 24–48 h aer 
euthanasia and OM collection, excluding when the tissue was 
cryopreserved. All cells used and considered in the different 
assays of this work originated from the pool obtained from 
the 10 rats from which OM was collected.
2.3. Isolation and In Vitro Expansion of OM-MSCs. All 
procedures related to cell isolation and expansion were 
performed under strict aseptic conditions, within the laminar 
flow hood. OM fragments were centrifuged and supernatant 
eliminated. OM fragments were carefully transferred to a sterile 
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harvested at 70–80% confluence. en, they were plated with 
culture medium in 10 wells of a 12-well plate (12 Flat Test plate, 
Orange Scientific®) at a density of 0.05 × 106 cells/cm2. For 10 
days, the number of cells from one well per day was determined. 
At the end of the 10 days, the PDT was defined through the 
method proposed by Lotfy et al. [47]. e formula used was 
PDT = CT/PDN, being CT the culture time (in this case, 10 
days) and PDN the population doubling number. e PDN was 
calculated using the formula PDN = 3.32(logXf − logXi) + 푆, 
being Xf  the cell harvested at the end of the subculture, Xi the 
cell number used as inoculum and 푆 the doubling level of the 
inoculum used to start the subculture being quantified. Here, 
as the value of 푆 is unknown, it was considered as 0. PDT was 
determined for 3 different moments, namely cells in P2-P3, P6-
P7, and P13-P14. For each passage, triplicates were considered.
2.4.3. Colony Forming Unit Assays. Colony Forming Units 
(CFUs) assay was performed according to the method 
indicated by Penfornis et al. [48]. Briefly, OM-MSCs at P3 
were maintained in culture until a confluence of 70–80%, 
followed by enzymatic detachment with 0.25% Trypsin-EDTA 
solution. Collected cells were diluted using a 1 : 2 serial dilution 
in growth medium to allow the plating of a density ranging 
from 10 to 80 cells in each well of a six-well plate. Cells were 
incubated for 14 days under standard conditions with daily 
monotorization to confirm the development of colonies. Aer 
this period, culture medium was removed and wells were 
stained with 0.5% (v/v) of Crystal Violet solution for 5–10 
min at room temperature. e number of colonies in each 
well was quantified using a magnifying glass (Leica Zoom 
2000, Meyer instruments®). Only visible colonies with more 
than 1 mm of diameter or with over 50 cells were considered. 
Overlapping colonies were not considered. e clonal 
efficiency (% of clonogenicity) was calculated using the formula 
(meannumber of colonies counted/total number of seeded cells)
×100. To establish the CFU value, six wells (푁 = 6) from a 
six-well plate were counted.
2.4.4. Cryopreservation and awing. OM tissue fragments, 
as well as OM-MSCs isolated and at different passages were 
subjected to cryopreservation and thaw cycles to determine 
the viability, subsequent cell performance and the efficacy of 
this method for cell and tissue preservation. Cells in culture 
were subjected to enzymatic detachment with 0.25% trypsin-
EDTA solution, collection and automatic counting. OM-MSCs 
were cryopreserved with culture medium and 10% Dimethyl 
sulfoxide (DMSO) (SigmaAldrich®) [49] in cryovials with 
at least 1 × 106 cells. e cryovials were then transferred to a 
freezing container with Isopropyl alcohol (Nalgene® Mr. Frosty®, 
ermoScientific®) for slow freezing (−1°C/minute) at −80°C. 
Aer a maximum period of 3 days, the cryovials were transferred 
to canisters inside a liquid nitrogen container (−196°C) for long-
term cryopreservation (LS750 Cryogenic Sample Storage, Taylor 
Wharton®). e process is identical for cryopreservation of OM 
fragments, with the difference that in this case the cryovial are 
placed about 15–20 minutes at 4° to allow penetration of DMSO 
into the tissue before its transference to −80°C.
e cryovial content was thawed using a water bath (37°C) 
for fast thawing. Inside the laminar flow hood, the cryovial 
Petri dish and fragments immersed in PBS to avoid dehydration. 
OM fragments were dissected into smaller pieces, reducing them 
to portions no larger than 1-2 mm2. Two phases were considered 
during the isolation method. In the first phase, an enzymatic 
digestion was performed to release OM-MSCs from the 
extracellular matrix. e reduced fragments were transferred to 
a tube, and a solution of 0.25% Trypsin-EDTA (Sigma-Aldrich®) 
for enzymatic digestion was added. Enzymatic digestion was 
performed in a water bath (37°C) for approximately 15 min, 
in constant agitation. Aer enzymatic digestion, the fragments 
were centrifuged and supernatant eliminated. Secondly, the 
fragments were transferred to 6-well tissue culture treated plates 
(Multiwell Cell Culture Plates 6 Wells, VWR®) at a density of 
1–3 fragments per well, letting them stand for 5–10 minutes 
to allow adherence to the plastic surface [25]. Once adherence 
was confirmed, preformulated culture medium consisting 
of Basal Medium (DMEM/F12 + GlutaMAX™ supplement, 
Gibco®) supplemented with 10% certified Fetal Bovine Serum 
(FBS) (One Shot Fetal Bovine Serum, Gibco®), 1.5% Penicillin-
Streptomycin and 1.5% Amphotericin B [26], in sufficient 
volume to cover the explants, was added to each well, carefully, 
so as not to disturb explants adhered to the plastic surface. 
Where floating fragments were identified (not adhered), the 
medium was removed and the process repeated minutes later. 
e plates were then incubated in standard conditions (37°C, 
5% CO2 humidified atmosphere). Wells were observed daily 
with an inverted phase contrast microscope (Axiovert 40 CFL, 
Zeiss®) in search for OM-MSCs radiating from the explants. 
Media were refreshed every 2-3 days.
Aer one week, cells were observed radiating from the 
explants and invading the wells of the plate. About 4 days later, 
the cells reached an intended confluence of 70–80%. At this 
stage, the medium and the explants were carefully removed. 
Each well was washed abundantly with PBS, and cells were 
detached using 0.25% Trypsin-EDTA solution and an incu-
bation of 3–5 min under standard conditions. e contents of 
all wells were then collected and centrifuged (1600 rpm, 10 
min), the supernatant eliminated and cells reseeded in a T75 
culture flask (Nunc™ EasyFlask™ 75 cm2, ermoScientific®) at 
a density of 2.1 × 106 cells/cm2.
2.4. Cell Behavior in Culture
2.4.1. Growth Curve and Cell Viability. Cells were maintained 
in culture over 35 days to determine their growth curve. 
Whenever a confluence of 70–80% was reached, a new cell 
passage was made, resulting in a total number of 15 passages. 
Each passage was performed by elimination of culture 
medium, washing with PBS, cell detachment with 0.25% 
Trypsin-EDTA solution and incubation during 3–5 min under 
standard conditions, centrifugation (1600 rpm, 10 min) and 
elimination of supernatant. To determine the number of cells 
and their viability at each passage, the Trypan blue exclusion 
cell assay [46], with counting of cells with an automatic 
counter (Countess II FL Automated Cell Counter, ermo 
Fisher Scientific®), was performed.
2.4.2. Population Doubling Time (PDT). OM-MSCs used 
to calculate PDT were thawed, maintained in culture, and 
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neutralization of acidity and for visualization by inverted phase 
contrast microscopy, distilled water was added to all wells. e 
final aim of this assay was the identification of chondrogenic 
aggregates and their coloration in blue due to the exposure to 
Alcian Blue solution.
2.5.3. Osteogenic Differentiation and Alizarin Red S 
Staining. For osteogenic differentiation, 8 × 103 cells/cm2 
were seeded into the wells of a 12-well plate. e plate was 
maintained under standard conditions for 4 days. Aer 
this period, the culture medium of 10 wells was replaced 
by complete osteogenic differentiation medium (StemPro® 
Osteogenic Differentiation Kit, Gibco®), and 2 wells were 
used as controls and maintained with the usual culture 
medium. Following the manufacturer’s instructions, media 
were replaced every 3-4 days and the cells maintained in 
differentiation for 21 days. At the end of this period, Alizarin 
Red S Staining protocol was performed using a commercial 
solution (Alizarin-Red Staining Solution, Milllipore®). e 
culture and differentiation media were removed, and the 
wells were gently washed with PBS. Cells were fixed with 4% 
formaldehyde for 30 minutes at room temperature, and the 
wells washed twice with distilled water. 40 mM of Alizarin 
Red solution was added to each well and the plate incubated 
for 30 minutes. Alizarin Red was then discarded, and wells 
were rinsed 3 times with distilled water until supernatant 
became clear. For visualization by inverted phase contrast 
microscopy, PBS was added to all the wells. e aim of this 
essay was to identify calcium containing osteocytes stained 
red aer exposure to alizarin Red solution.
2.5.4. Neurogenic Differentiation. For neurogenic 
differentiation, 4 × 103 cells/cm2 were seeded into the wells 
of a 12-well plate. e plate was maintained under standard 
conditions, and media replaced every 3-4 days until a 
confluence of 70–80% was reached. Media were removed from 
all wells and 8 of them received neurogenic differentiation 
medium (MSC Differentiation Medium, PromoCell®), and 2 
wells were used as controls and maintained with the usual 
culture medium. e plate was Incubate for 5 days, and media 
changed every 48 hours.
2.6. Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR). RT-PCR targeting specific genes expressed by 
undifferentiated OM-MSC cells, in passages 4 and 6 was 
performed. e expression of 19 genes was analyzed to 
allow the identification of genes associated with markers 
included in the minimum criteria for the characterization of 
cells as MSCs according to the ISCT [10] and markers for 
differentiation. ree genes used as markers for pluripotent 
stem cells (NANOG, Oct4, Sox2), four genes used as MSC 
markers (CD105, CD90, CD73, CD44), two genes used 
as hematopoietic markers (CD45, CD34), and genes used 
as markers of differentiations: osteogenic (BSP, Runx2), 
chondrogenic (Coll II, Aggrecan), adipogenic (Ap-2, AdipoQ), 
neurogenic (NGF and GDNF), tenogenic (Tenomodulin) and 
musclogenic (Desmin) were analyzed. GAPDH was used as 
housekeeping gene. For identification of gene expression, 
a 96-well plate (Prime PCR Custom Plate 96 Well, Bio Rad 
contents were quickly collected, centrifuged, and the super-
natant discarded. OM-MSCs were resuspended in culture 
medium, counted, cultured, and maintained under standard 
conditions. e procedure for the OM fragments is identical, 
the explant plating aer enzymatic treatment being performed 
aer thawing.
2.5. Differentiation Protocols. For all differentiation protocols, 
cells in P4 aer thawing were used.
2.5.1. Adipogenic Differentiation and Oil Red O Staining. For 
the adipogenic differentiation protocol, 1 × 104 cells/cm2 were 
seeded in the wells of a 12-well plate, with addition of culture 
medium. e plate was incubated under standard conditions 
for 4 days. Aer this period, the culture medium of 10 wells 
was replaced by complete adipogenesis differentiation medium 
(StemPro® Adipogenesis Differentiation Kit, Gibco®) 2 wells 
were used as controls and maintained with the usual culture 
medium. Following the manufacturer’s instructions, the 
media were replaced every 3-4 days and the cells maintained 
in differentiation for 14 days. At the end of this period, Oil 
Red O staining protocol was performed using a handmade 
solution. e culture and differentiation media were removed, 
and the wells were gently washed with PBS. Cells were fixed 
with 4% formaldehyde (3.7–4% buffered to pH7, reference# 
252931.1315, Panreac AppliChem®) for 10 minutes at room 
temperature, and the wells washed 3 additional times with 
PBS. Oil Red O solution was added to each well and the plate 
incubated for 10–20 minutes at room temperature. Oil Red O 
was discarded, and any excess dye removed by several washes 
with PBS. PBS was added to each well for visualization. e 
aim of this assay was the identification of intracytoplasmic 
lipid vacuoles and their red coloration due to the exposure to 
the Oil Red O solution.
2.5.2. Chondrogenic Differentiation and Alcian Blue 
Staining. awed OM-MSCs were automatically counted and 
% cell viability determined. e cells were then centrifuged, 
supernatant removed, and the pellet resuspended in culture 
medium to generate a cell suspension with 1.6 × 107 viable 
cells/ml. To generate micro-mass cultures, 5 μl droplets of the 
cell suspension were placed in the center of 10 wells of a 96-well 
plate (Cell culture plates, 96-well, VWR®), in order to induce 
chondrogenic differentiation. e plate was maintained under 
standard conditions for 2 hours. Aer this time, chondrogenic 
differentiation medium (StemPro® Chondrogenesis 
Differentiation Kit, Gibco®) was added to 8 wells, as 2 wells were 
considered as control and to these, usual culture medium was 
added. Following the manufacturer’s instructions, media were 
replaced every 3-4 days and cells maintained in differentiation 
for 14 days. At the end of this period, the Alcian Blue staining 
protocol was performed (Alcian Blue 8GX, Sigma-Aldrich®). 
e culture and differentiation media were removed, and the 
wells were gently washed with PBS. Cells were fixed with 4% 
formaldehyde during 20 minutes at room temperature, and 
the wells washed 3 additional times with PBS. Alcian Blue 
solution was added to each well and the plate incubated for 30 
minutes at room temperature. Alcian Blue was then discarded 
and wells were rinsed 3 times with acetic acid 3% (v/v). For 
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RQ = 2−(ΔΔCt) Genes with RQ values <0.5 are down-regulated 
and with RQ values >2 are up-regulated.
2.7. Cytogenetic Analysis. For evaluation of the karyotype, 
OM-MSCs in three different passages (P5, P8 and P11) were 
submitted to cytogenetic analysis to determine chromosomal 
stability in terms of chromosome number and occurrence 
of neoplastic changes. For all passages, 70–80% confluence 
was reached, and culture medium was changed and 
supplemented with 10 μg/ml colcemid solution (KaryoMAX® 
Colcemid™ Solution, Gibco®). Aer 4 h, the OM-MSCs were 
collected and resuspended in 8 mL of 0.075 M KCl solution, 
followed by incubation under standard conditions for 15 
minutes. Aer a centrifugation (1700 rpm), 8 ml of ice-
cold fixative comprising methanol and glacial acetic at a 
proportion of 3 : 1, was added and mixed together and the 
cells were centrifuged again. ree fixation rounds were 
carried out. Aer the last centrifugation, the suspension 
of OM-MSCs was spread over glass slides. Karyotype 
analysis was performed by one scorer on Giemsa-stained 
cells. For the different passages, a specific number of cells in 
metaphase were evaluated dependent on the number of cells 
with a normal karyotype identified, guaranteeing a better 
representation of the population under study.
2.8. Immunohistochemical Analysis. Early passage (P5) of 
OM-MSCs was submitted to immunohistochemical analysis 
to detect specific antigens (Table 1). Cells were maintained 
in culture until a confluence of 70–80% was reached, then 
enzymatic detachment was performed with 0.25% Trypsin-
EDTA solution and a paraffin cytoblock (Surein® Preserve 
Cell solution®, Cytoglobe GmbH®) was accomplished. Sections 
were cut at 2 μm, deparaffinized, dehydrated and submitted to 
immunohistochemical analysis using the Novolink™ Polymer 
Detection Systems (Leica Biosystems®) kit, according to 
the manufacturer’s instructions. Information regarding the 
primary antibodies and antigen retrieval methods used in the 
study are summarized in Table 1. e antibodies were selected 
to confirm the mesenchymal origin of OM-MSCs (vimentin 
and c-Kit), to discard an endothelial (CD31) and epithelial 
(Cytokeratin AE1/AE3) origin and to identify the expression 
of neural (synaptophysin) and glial markers (GFAP).
e samples were observed, evaluated, and photographed 
using the microscope Eclipse E600 (Nikon®) and the soware 
Imaging Soware NIS-Elements F Ver4.30.01 (Laboratory 
Imaging®). Immunoexpression of the different markers was 
scored for the percentage of labeled cells (<5%; 5–80%; >80%) 
and labeling intensity (0, negative; +, weak; ++, moderate; 
Laboratories®) was created with 19 predesigned primers for 
the indicated genes (Supplementary Material – Table S1).
2.6.1. RNA Isolation and cDNA Synthesis. Isolation of RNA 
was performed with the Aurum™ total RNA Mini Kit (Bio Rad 
Laboratories®), according to the manufacturer’s instructions. 
Briefly, a 2 × 106 cells pellet was lysed with a lysis solution, 
DNA removed with a DNAase I enzyme and eluted with 80 μl 
of an elution solution. RNA was stored at −80°C for later use. 
Before cDNA synthesis, the amount and purity of the RNA 
was determined by UV-spectrophotometry by measuring the 
A260/A280 (indicator of protein contamination) and A260/A230 
(indicator of polysaccharide, phenol, and/or chaotropic salt 
contamination) absorbance in a Nanodrop spectrophotometer 
(Implen, Isaza). Purity values considered acceptable range 
from 2–2.2 to A260/A280 and from 1.8–2.2 to A260/A230 [50].
e first strand cDNAs were synthesized from 3.51 μl of 
total RNA in 20 μl final volume, using the iScript™ cDNA 
Synthesis Kit (Bio Rad Laboratories®) according to the man-
ufacturer’s instructions. e complete reaction mix was incu-
bated in the thermal cycler (T100™ ermal Cycler, Bio Rad 
Laboratories®) using the manufacturer’s time and temperature 
guidelines for the aforementioned kit.
2.6.2. Quantitative RT-PCR Assay. RT-PCR assay was 
performed using the CFX96 Touch™ Real-Time PCR 
Detection System (Bio Rad Laboratories®) under standard PCR 
conditions and using itaq™ Universal SYBR Green Supermix 
(Bio Rad Laboratories®) according to the manufacturer’s 
guidelines. Plates were read in the Real-Time PCR Detection 
System. Each pair of primers targeting the genes was used to 
analyze their expression in OM-MSCs. Plates containing the 
mix targeting the 19 genes were subjected to the temperature 
cycles indicated by the manufacturers. Once the RT-PCR was 
finished, the gene expression was analyzed. To confirm the 
specificity of the product, an analysis of the melting curve 
was also performed.
e values of threshold cycle (Ct) <29 are considered 
strong positive reactions indicative of abundant target nucleic 
acid in the sample; Ct between 30 and 39 are considered pos-
itive reactions indicative of moderate amounts of target nucleic 
acid; Ct >39 correspond to weak reactions and indicate min-
imum target nucleic acid values or environmental contami-
nation. For each passage, the ΔCt value was calculated using 
the formula ΔCt = Cttarget gene − Cthousekeeping gene. Fold differ-
ences between the two passages were calculated using the 
standard ΔΔCt with the formula ΔΔCt = ΔΔCtP6 − ΔΔCtP4. 
e relative quantification (RQ) was calculated by the formula: 
Table 1: List of antibodies investigated, dilutions and antigen retrieval methods applied in the immunohistochemical analysis.
Antibody Clonality Manufacturer Dilution Antigen retrieval
Cytokeratin Clone AE1/AE3 Invitrogen®, ermo Fisher Scientific® 1/200 Water bath/20 min
Vimentin Clone V9 DAKO®, Agilent Technologies® 1/1200 Water bath/20 min
CD31 Clone JC70A DAKO®, Agilent Technologies® 1/200 Pepsine
Synaptophysin Clone SP11 ermo Fisher Scientific® 1/100 Water bath/20 min
c-Kit Polyclonal DAKO®, Agilent Technologies® 1/450 Water bath/20 min
GFAP Polyclonal Millipore® 1/2000 Water bath/20 min
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significant. Significance of the results is showed according 
to 푃 values by the symbol (∗), (∗) corresponding to 0.01 
≤ P < 0.05, (∗∗) to 0.001 ≤  푃 < 0.01, (∗ ∗ ∗) to 0.0001 
≤ 푃 < 0.001 and (∗ ∗ ∗∗) to 푃 < 0.0001.
3. Results
3.1. Isolation and In Vitro Expansion of OM-MSCs. e 
procedure performed to isolate OM-MSCs from OM is mixed, 
comprising explant plating aer an enzymatic treatment. 
is method showed efficacy and allowed observation of 
OM-MSCs radiating from the explants and harvesting was 
performed within 1 to 2 weeks aer plating of the explant 
(Figure 1(a)).
3.2. Cell Behavior in Culture. Both cells observed radiating 
from the explants and those identified in culture showed 
clear plastic adhesion and mostly fibroblast-like morphology, 
an essential feature to characterize cells as MSCs (Figures 
1(b)–1(e)). Considering earlier passages, adhesion time 
was longer and cell growth and proliferation slower. Cell 
performance, as for adhesion and proliferation, was maximal 
between P5 and P8. At this phase, lower time for adherence, 
unequivocal fibroblast-like shape, and shorter time to reach 
desired confluence was observed. Performance decreased 
progressively aer passages P8-P9.
3.2.1. Growth Kinetics and Cell Viability. e growth curve was 
achieved by analyzing the OM-MSCs over 15 passages (P15). 
e number of cells quantified remained stable in the first 
two passages, with an exponential increase up to the seventh 
passage. Aer this phase, a marked decrease in the number 
of cells quantified was observed, and this value remained 
+++, strong). Immunoreactivity was considered as positive 
when distinct nuclear and cytoplasmatic staining was recog-
nized in at least 5% of the cells.
2.9. OM-MSCs’ Conditioned Medium Analysis – Secretome. To 
identify specific chemokines and growth factors produced 
and secreted by OM-MSCs, conditioned medium (CM) was 
analyzed. For the conditioning, OM-MSCs in early passage 
(P4) were applied. Once 70–80% confluence was reached, the 
culture medium was removed, and the culture flask gently 
washed with PBS 5 times. e culture flask was further 
washed twice with culture medium. Subsequently, basal 
culture medium without supplementation with antibiotic, 
antimycotic, or FBS was added to the culture flask, which 
was incubated under standard conditions for 48 h. Aer 
this period, the culture medium rich in factors secreted by 
the cells (conditioned media) was collected, centrifuged, 
and the supernatant collected. CM was stored at −20°C 
and subsequently analyzed by Multiplexing LASER Bead 
analysis (Eve Technologies, Canada) to search for a specific 
set of biomarkers (TM-Featured Cytokine Array/Chemokine 
Array 8-plex (RECYT-08-204)). e biomarkers studied were 
Interferon gamma (IFN-γ), monocyte chemotactic protein-1 
(MCP-1), tumor necrosis factor alpha (TNF-α), vascular 
endothelial growth factor (VEGF) and several interleukins 
(IL-2, IL-4, IL-6, IL-18). Six independent samples of CM were 
analyzed.
2.10. Statistical Analysis. Statistical analysis was performed 
using the soware GraphPad Prism version 6.00 for Windows 
(GraphPad Soware, La Jolla California USA). When 
appropriate, data were expressed as mean ± SEM. Comparisons 
between groups were performed with an analysis through a 
parametric test. A value of 푃 < 0.05 is considered statistically 
(a)
(b) (c)
(d) (e)
Figure 1: Magnification: 100x; Scale Bar: 100 μm. (a) OM fragment plated by the explant method aer enzymatic digestion. 1 week aer plating, 
cells with morphological characteristics of MSCs irradiating from the explant can be observed; (b)–(e): morphology of OM-MSCs in culture: 
(b) P2, 30–40% confluence; (c) P5, 50–60% confluence; (d) P7, 70–80% confluence, ideal moment for passage; (e) P9, 90–100% confluence.
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3.3.2. Chondrogenic Differentiation and Alcian Blue 
Staining. e ability of OM-MSCS for chondrogenic 
differentiation was confirmed by observation of chondrogenic 
aggregates and extracellular matrix stained blue due to the 
exposure of the proteoglycans to Alcian Blue solution 
(Figures 6(c) and 6(d)).
3.3.3. Osteogenic Differentiation and Alizarin Red Staining. e 
ability of OM-MSCS for osteogenic differentiation capacity was 
confirmed by identification of calcium containing osteocytes 
and extracellular calcium deposits red stained due to the 
exposure to Alizarin Red solution (Figures 6(e) and 6(f)).
3.3.4. Neurogenic Differentiation. On day 1 aer replacement 
of the culture medium by neurogenic induction medium, clear 
morphological alterations were already observed in the OM-
MSCs that acquired a neuroglial-like shape with development 
of axon and dendrite-like cell structures (Figures 6(g)–6(i)). 
e neuroglial-like morphology was maintained throughout 
the 5 days of observation, but an increase in the mortality rate 
and number of cell debris in suspension were also identified.
3.4. RT-PCR. Table 2 shows the Ct average values for each 
gene, ΔCt, ΔΔCt and RQ values. According to the analysis 
performed, both samples showed purity, allowing their use 
in subsequent phases. Cells at P4, CD90 and CD44 showed 
Ct values <29. All other genes, except for BSP, had average 
Ct values between 30-39, indicating positive reactions and 
moderate amounts of target nucleic acid in the sample. Cells 
at P6, once again CD90 and CD44, and also Ap-2 showed 
Ct < 29, that is, abundance of the target nucleic acid in the 
sample, and all other genes presented values between 30 and 
39. In both passages, CD45, CD34 and AdipoQ genes had no 
detectable expression. Statistically significant differences were 
identified between ΔCt values of the genes Oct4, Sox2, CD105, 
CD90, CD73, CD44, BSP, Coll II, Ap-2, Tenomodulin an 
Desmin for P4 and P6 (Figure 7). Comparing the two passages, 
changes were observed in fold-expression of the genes. At P6, 
NANOG, OCT4, Sox2, CD105, CD90, CD73, CD44, GDNF, 
Tenomodulin and Demin appear down-regulated and Ap-2, 
BSP, Coll II, aggrecan and NGF appear up-regulated.
stable until P15 (Figure 2(a)). Cell viability was lower in the 
first passage. Between passage 2 and passage 12% viability 
remained between 99% and 100%. In the last three passages 
the viability decreases progressively (Figure 2(b)).
3.2.2. PDT. e growth curve for cells growing in culture had 
an identical shape for the three determinations of PDT with 
respect to the exponential and stationary phases (Figure 3). 
Regarding the lag phase, it was easily identifiable in passages 
P2-P3 and P13-P14, being not visible in the graph P6-P7. e 
mean value of PDT was 92.87 ± 0.04 hours for the passage 
P2–P3, 80.94 ± 0.79 hours for P6-P7 and 113.99 ± 18.01 hours 
for P13-P14 (Figure 4).
3.2.3. Colony Forming Unit Assays. CFU assays allowed to 
confirm the ability of OM-MSCs to generate new fibroblast 
colonies from single cells. Aer 14 days of incubation, it was 
possible to identify an average of 35.33 ± 3.56 colonies with 
spindle morphology per well, approximately 212 colonies 
up to 1 mm formed from around 480 seeded cells. e % of 
clonogenicity was 44.16 ± 4.45% (Figure 5).
3.2.4. Cryopreservation and awing. OM-MSCs submitted to 
cryopreservation and thawing procedures showed no detectable 
performance changes. Independently of the passage in which the 
cryopreservation occurred, aer thawing, cell adhesion to the 
plastic surface occurred in few hours, confluence of 70–80% was 
reached between 3 and 4 days and the expected morphology for 
OM-MSCs (fibroblast-like shape) was also observed. awing 
of cells below P5 (푁 = 12), the % cell viability determined 
by Trypan blue exclusion cell assay was 97.83 ± 1.07%, with 
viability above 95% for all the samples tested.
3.3. Differentiation Protocols
3.3.1. Adipogenic Differentiation and Oil Red O Staining. e 
ability of OM-MSCS for adipogenic differentiation was 
confirmed by observation of morphologic changes (large cells 
with a rounded shape) and red stained lipid vacuoles in the 
cytoplasm due to exposure to Oil Red O solution. (Figures 
6(a) and 6(b)).
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Figure 2: (a) OM-MSCs’ growth curve over 35 days (15 passages); (b) Variation of % cell viability over 35 days (15 passages).
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Figure 3: Cell growth of OM-MSCs over 10 days of culture in P2-P3 (a), P6-P7 (b), and P13-P14 (c).
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Figure 4: PDT for the different passages (mean ± SEM).
Figure 5:  CFU assay: observation of individualized colonies in a 
6-well tissue culture treated plate, stained with crystal violet solution.
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3.7. OM-MSCs’ Conditioned Medium Analysis – Secretome. e 
mean concentration of each biomarker in the CM under 
analysis is shown in Table 4 and Figure 10.
4. Discussion
Even though multipotent cells in the OM has been known 
for a long time [17], only recently the OM-MSCs have been 
 adequately identified. Efforts have been made to characterize 
these cells in different species, and to establish appropriate 
collection, isolation, characterization, storage, and experi-
mental application methods. In the present work, an exten-
sive characterization of rat OM-MSCs was carried out to 
3.5. Cytogenetic Analysis. Cytogenetic evaluation allowed 
the identification of a high percentage of cells with a normal 
karyotype for the species (42, XY) for all passages (Figure 8), 
although a small decrease in this percentage was observed in 
passages P8 and P11 compared to passage P5. Regarding the 
mitotic index, the values are normal for passages P5 and P8 
and low for passage P11 (Table 3).
3.6. Immunohistochemical Analysis. Immunohistochemistry, 
OM-MSCs showed weak immunoreactivity for synaptophysin 
(comprising about 5% of cell population), moderate for c-kit 
(comprising 5–80%) and strong staining for GFAP and 
Vimentin (involving >80% of the cells). Cells were negative 
for AE1/AE3 and CD31 immunomarkers (Figure 9).
Adipogenic
Control Dierentiation
Chondrogenic
Ostepgenic
Neurogenic
(a) (b)
(c) (d)
(e)
(g) (h) (i)
(f)
Figure 6: Cell differentiations. Magnification: 100x; Scale bar: 100 μm. Adipogenic differentiation: (a) control; (b) presence of large round 
shaped cells (black arrow) and red stained lipid vacuoles inside the cytoplasm (white arrow); chondrogenic differentiation: (c) control; (d) 
presence of chondrogenic aggregate and extracellular matrix stained in blue (black arrow); osteogenic differentiation: (e) control; (f) presence 
of calcium containing osteocytes (black arrow) and extracellular calcium deposits (white arrow) stained in red; neurogenic differentiation: 
(g) control; (h) 24 h aer addition of neurogenic induction medium, the cells acquired a neuroglial-like shape with development of dendrite 
(black arrow) and axonal-like (white arrow) cell structures (i) 72 h aer addition of neurogenic induction medium.
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to difficulties in comparing the results obtained in different 
laboratories and in different works, and many of these differ-
ences can be explained through the variations in the estab-
lished protocols [11].
confirm their characteristics of stem/stromal cells and their 
potential use in future regenerative therapies. e authors 
opted for a detailed description of all the procedures per-
formed, since variations in manufacturing processes can lead 
Table 2: Ct, ΔCt, ΔΔCt and RQ values for all genes under study for P4 and P6. nd = nondefined.
Target gene
P4 P6
Ct average OM-MSCs ΔCt OM-MSCs Ct average OM-MSCs ΔCt OM-MSCs ΔΔCt RQ Regulation
Nanog 35.9 ± 0.9 9.7 38.2 ± 0.0 13.5 5.4 0.0 ↓
Oct4 35.3 ± 0.0 9.1 36.5 ± 0.0 11.9 4.3 0.1 ↓
Sox2 36.0 ± 0.0 9.8 36.0 ± 0.0 11.3 3.0 0.1 ↓
CD105 33.9 ± 0.0 7.7 34.5 ± 0.0 9.8 3.7 0.1 ↓
CD90 26.2 ± 0.2 −1.5 26.4 ± 0.0 1.7 3.2 0.1 ↓
CD73 32.9 ± 0.3 6.7 32.9 ± 0.3 8.2 3.0 0.1 ↓
CD44 29.4 ± 0.1 3.2 28.1 ± 0.1 3.4 1.7 0.3 ↓
CD45 nd nd nd nd nd nd nd
CD34 nd nd nd nd nd nd nd
BSP 40.6 ± 0.0 14.4 35.8 ± 0.0 11.1 −1.8 3.5 ↑
Runx2 35.1 ± 0.6 8.9 31.8 ± 0.0 7.1 −0.3 1.2 N
Coll II 36.8 ± 0.0 10.6 30.3 ± 0.3 5.7 −3.4 10.5 ↑
Aggrecan 36.6 ± 0.6 10.4 31.6 ± 0.4 7.0 −1.9 3.8 ↑
Ap−2 33.8 ± 0.4 7.6 27.8 ± 0.1 3.2 −2.9 7.5 ↑
AdipoQ nd nd nd nd nd nd nd
NGF 36.9 ± 0.7 10.7 31.7 ± 0.4 7.0 −2.2 4.5 ↑
GDNF 34.4 ± 1.7 8.2 33.0 ± 0.0 8.4 1.7 0.3 ↓
Tenomodulin 35.0 ± 0.0 8.8 35.0 ± 0.0 10.4 3.0 0.1 ↓
Desmin 36.2 ± 0.0 10.1 36.3 ± 0.1 11.6 3.1 0.1 ↓
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Figure 7: ΔCt Values for the different genes under study in OM-MSCs for P4 and P6. Higher delta-CT values represent lower expression 
(mean ± SEM).
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manufacturing practices ensured the maintenance of healthy 
and functional cell cultures with no contamination throughout 
the study period and in all the procedures performed.
Mixed isolation of OM-MSCs from OM fragments was 
effective. In the period between 1 and 2 weeks aer plating of 
explants, it was possible to observe irradiant spindle-shaped 
cells in the plate, as detected in other works performed with 
rat [22] and other species [34, 46]. Although some authors 
prefer a simple method without performing enzymatic diges-
tion of the OM fragments [28, 53], the enzymatic treatment 
before plating the explants did not affect the characteristics of 
OM-MSCs and was corroborated by other authors [30]. Aer 
isolation of OM-MSCs and their culture, it was possible to 
observe their features of MSCs [10], namely plastic adhesion 
and fibroblastic-like shape, as confirmed by other authors [29, 
54]. For higher passages, morphological alterations could be 
observed, with the cells appearing more rounded and losing 
the characteristic elongated shape, some of them detaching, 
and increasing the amount of cellular debris suspended in the 
medium. ese changes associated with a high number of 
passages are common and characteristic of MSCs in long-term 
cultures [55].
e growth kinetics can be studied through the growth 
curve and the PDT, concepts that should not be considered as 
synonymous. While the growth curve allows comparing the 
number and characteristics of cells at the same degree of con-
fluence along the different passages, with the number of cells 
being determined only at the time of the passage itself, PDT 
shows the time it takes for the number of cells in culture to 
increase to double and is obtained by daily determinations of 
cell numbers along the same passage. rough the determi-
nation of PDT it is also possible to plot growth curves over 
the days of the same passage. While the two studies can be 
done together as in the present work, PDT is a better indicator 
of cell performance since cell growth can vary greatly between 
donors and methods of preparation. PDT correlates directly 
with genetic stability and with replicative senescence, linked 
to loss of potency. In addition, PDT makes it possible to ana-
lyze and compare different studies easily [56]. e growth 
curve observed is identical to that described for OM-MSCs 
from other species [26]. Growth and cell viability curves 
showed poorer cell vitality in the lower and higher passages, 
in which a lower number of cells in the passage and lower cell 
viability were observed. Cell viability should be at least 95% 
for healthy cultures [57] and from P13 values lower than these 
were observed. Growth curves analyzed for PDT determina-
tion confirmed these observations. e growth of MSCs must 
occur in 3 phases: initial lag phase, fast and exponential growth 
phase, and stationary phase [58]. ese three phases are pres-
ent in the growth curves of OM-MSCS at the 3 moments con-
sidered. Finally, PDT is lower for P7–P8, followed by P2–P3, 
and passage P13–P14 has the worst result. Recalling, the lower 
the PDT, the faster an increase to twice in cell efficiency. e 
PDT values observed in this work are higher than those 
described for rat’s OM-MSCs in other works [29]. All these 
findings, together with the observed behavior of OM-MSCs 
in culture, confirmed the occurrence of senescence phenom-
ena during extended periods culture [59]. Senescence phe-
nomena start when MSCs are cultured and progressively 
Although the niche of OM-MSCs is helpful because of 
their peripheral position in the body, the remote location of 
the olfactory recess and OM within the nasal cavity and the 
intricate anatomic characteristics of the nasal turbinates that 
make access to this area, significantly hamper the OM tissue 
collection [51]. e protocol applied in this work is a fast and 
efficient alternative for collection of OM fragments from the 
rat’s nasal cavity, with no need for complex procedures or spe-
cific surgical instruments. Care should be taken to avoid an 
overly aggressive approach to the nasal cavity that may trigger 
hemorrhage and contamination of OM. [24] Solutions for 
transporting and storing fragments of OM before processing 
are also important for tissue preservation and integrity of 
OM-MSCs. Here, as in all procedures, we chose to use PBS 
because of its ability to prevent cells rupturing or shriveling 
up due to osmosis [52]. Antibiotics and antimycotics were 
used because of collection procedure of OM and its anatomical 
location, prone to contamination, as to avoid bacterial or fun-
gal contaminations.
Aseptic conditions were maintained when performing all 
procedures of isolation and culture. For cell culture, besides 
the antibiotic and antimycotic use already mentioned, the cul-
ture medium comprised a basal medium rich in glucose, 
amino acids, and vitamins, and FBS for animal-derived growth 
supplementation. All culture media were sterile filtered 
(Acrodisc® Syringe Filters with Supor® Membrane, 0.2 μm), 
and cell culture incubations was performed under standard 
conditions (37°C, 5% CO2 humidified atmosphere). All these 
Figure 8: OM-MSCs’ karyotype (P8), showing structural normality, 
normal number of chromosomes (42, XY) and absence of neoplastic 
alterations. ese characteristics demonstrate the chromosomal 
stability of these cells.
Table 3: Percentage of normal karyotypes and mitotic indexes of 
OM-MSCs in P5, P8, and P11.
Passage % Cells with normal karyotype (42, XY) Mitotic Index
P5 85% Normal
P8 62% Normal
P11 58, 80% Low
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clonogenicity with values close to those found in the literature 
for the specie [29].
Cryopreservation is an important method to preserve 
MSCs, allowing almost immediate availability of cells for clin-
ical application in cell therapies and regenerative medicine. 
During the cryopreservation and subsequent thawing process, 
it is important that MSCs maintain their intrinsic properties, 
namely their culture behavior, their immunomodulatory char-
acteristics, and the ability to multilineage differentiation [63]. 
e changes and effects caused by the different methods of 
cryopreservation, medium, cryoprotectants, temperature, and 
duration of cryopreservation are relatively well defined [64], 
but there is little clear information in this subject regarding 
MSCs of veterinary origin. e choice of the cryopreserving 
agent is an important aspect. In the present work we opted for 
the use of DMSO due to the evidence that this agent guarantees 
greater cell viabilities aer the cryopreservation and thawing 
cycle. Its mechanism of action during cryopreservation is 
based on its ability to penetrate cells and remove water from 
them, thus preventing intracellular ice formation and cell rup-
ture [65]. Some studies indicate that DMSO has tumorigenic 
potential when in contact with cells, but the possible similar 
effect of other cryoprotective agents has not yet been ade-
quately established [66, 67]. Other works also indicate that 
DMSO above 4°C can become cytotoxic [66]. To avoid this 
effect, during the thawing phase it is ensured that there is no 
complete thawing of the ice within the cryovial, that the cry-
opreservation solution is readily centrifuged, and the super-
natant containing the DMSO eliminated. e duration of 
maintenance of MSCs in cryopreservation may also affect their 
characteristics [68]. Cells used in this work did not exceed 
twelve months of cryopreservation, so it is not possible to 
anticipate possible negative effects from longer storage 
worsens over time and along passages, with gradual decreasing 
of proliferation potential, telomere shortening and impairment 
of functions [55, 60]. Morphologically the senescence mani-
fests through debris in the medium and granules in the cyto-
plasm of the cells [61]. All of these phenomena were observed 
in OM-MSCs under study, even though earlier studies have 
reported self-renewal in long-term cultures of olfactory neu-
ro-epithelial derived progenitors by maintenance of telomer-
ase activity and lack of apoptotic activity [23]. us, rat’s 
OM-MSCs should be assigned to cell therapies ideally in early 
stages of in vitro culture, ideally between P4 and P8.
e determination of CFUs is a good method to assess 
self-renewal efficiency and the ability of MSCs to originate 
colonies from a single precursor cell [62]. e number of col-
onies formed from a specific number of seeded cells represents 
the colony-forming efficiency and can be defined as the clo-
nogenicity of the cell population. In the present study, as in 
other works focusing on OM-MSCs [15, 26], cells originated 
several colonies with spindle morphology, presenting a 
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Figure 9: Immunolabeling of rat OM-MSCs (P5), Magnification: 600x: (a) AE1/AE3 (0); (b) Vimentin (+++); (c) CD31 (0); (d) Synaptophysin 
(+), (the black arrow highlights focal and membranous positive immunostaining); (e) c-Kit (++); (f); GFAP (+++). Insets show the respective 
negative controls for each immunomarker.
Table 4: Mean normalized concentration of each biomarker in the 
CM of OM-MSCs (mean ± SEM).
Biomarker Mean normalized concentration
IL-4 0.34 ± 0.11
IL-2 0.4 ± 0.22
IL-6 0.32 ± 0.3
IFN-γ 0.07 ± 0.1
IL-18 0.08 ± 0.10
MCP-1 0.13 ± 0.9
TNF-α 0.31 ± 0.04
VEGF 0.19 ± 0.13
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CD34 excludes a primitive hematopoietic origin [70] and the 
absence of CD45 excludes a leukocyte origin [71]. AdipoQ is 
an adipogenic gene [72]. Considering the previously men-
tioned ability of OM-MSCs for adipogenic differentiation, the 
nonexpression of this gene is unexpected. Both in P4 and P6 
some genes presented a Ct < 29, that is, abundant target nucleic 
acid in the sample. CD90 is used as a minimum criterion for 
MSCs’ classification [15], being related to cell repair and cell 
to cell interactions phenomena [11]. Its high genetic expres-
sion is expected and confirmed by other studies of OM-MSCs 
[26]. CD44 is used as a specific marker for classifying human 
OM-MSCs [73], although the classification for veterinary cells 
does not always consider this marker [11]. Since CD44 is 
closely related to cell adhesion phenomena [74], its high 
expression at OM-MSCs is also expected. AP-2 gene, related 
to the capacity of adipogenic differentiation [75] also shows 
high expression in P6, although with a lower value in P4. CD73 
and CD105, respectively related to adenosine production [76] 
and vascular hemostasis phenomena [77], are also considered 
as minimum criteria for classification of OM-MSCs. In both 
passages their Ct values were lower than 35, so that their 
genetic expression can be considered moderately high. Still 
with Ct values below 35 are several genes associated with spe-
cific markers of osteogenic (Runx2 in P6) [78], chondrogenic 
(Coll II in P6, Aggrecan in P6) [79], adipogenic (AP-2 in P4) 
[75], and neurogenic (NGF in P6, GDNF in P4 and P6) [80, 
81] differentiations, confirming the ability to tridifferentiation 
and the potential for differentiation in mesodermal lines [29]. 
Even with higher Ct values, other indicators of tenogenic dif-
ferentiation (Tenomodulin in P4 and P6,) [82] osteogenic 
differentiation (BSP in P6) [83] and musclogenic differentia-
tion (Desmin in P4 and P6) [84] also presented relevant gene 
expression. More irregular is the value of Ct greater than 35 
for genes related to multipotency capacity such as NANOG, 
Oct4 and Sox2 in both passages. ese markers are considered 
regulators of pluripotency of MSCs [85], although some stud-
ies raise doubts as to the influence of all these markers in this 
multipotentiality [86]. ese genes are also down-regulated at 
P6 compared to P4, indicating a possible loss of propensity for 
pluripotential activity the cell population at higher passages. 
In contrast, most of the differentiation-related genes are 
up-regulated at P6, which may be explained by an increase in 
the propensity of these cells for specific differentiations in the 
interval for which the maximum functional activity of 
OM-MSCs was established (P5-P8). is suggests that these 
cells, although with greater up-regulation of genes associated 
with pluripotency at earlier stages, at around passage 6, present 
a greater propensity for specific differentiations, possibly being 
this the ideal moment for clinical application. ese results 
should be interpreted with caution. e minimum criteria 
used to characterize human MSCs are also applied to MSCs 
of animal origin, even though several studies have shown that 
there is no precise parallelism in the expression of these sur-
face markers [29, 87–91]. In addition, in-depth studies are 
needed to identify markers that can be considered as unique 
and unambiguous in the characterization of veterinary MSCs 
[92]. However, considering current knowledge, RT-PCR cor-
roborates the mesenchymal origin of the rat’s OM-MSCs and 
their tendency for multidifferentiations.
periods. In the procedures performed using the described 
protocol of cryopreservation and thawing, no specific altera-
tions were observed regarding cell adherence aer plating, cell 
confluence, number of cells and viability during cell passage.
Although multipotent capacity of MSCs is widely estab-
lished in several species and in different niches [11], the capac-
ity for tridifferentiation continues to be used as a minimum 
criterion for identification and characterization of these stem/
stromal cells [10]. In the present study, aer the establishment 
of specific differentiation protocols, OM-MSCs showed a 
capacity for adipogenic, osteogenic, and chondrogenic differ-
entiation in culture. e capacity for differentiation into a 
neuroglial-like lineage was also tested and confirmed, although 
further studies are needed to determine the actual efficacy for 
neurogenic differentiation. e early transformation of 
OM-MSCs into a neuroglial-like lineage following exposure 
to neurogenic differentiation medium could also be observed, 
but it is important to note that simple morphological differ-
entiation is not sufficient to consider the functional efficacy 
of neurogenic differentiation and further studies are needed 
to determine this effectiveness. ese capabilities confirm the 
results obtained by other studies focusing on OM-MSCs 
[15, 26, 28, 29, 32, 69].
RT-PCR allowed to quantify the gene expression of 19 
genes associated with OM-specific markers on OM-MSCs and 
identify changes in their fold-expression between passages. 
e determination of the purity by spectrophotometry allowed 
to confirm the absence of contamination by different origins 
in the RNA samples used to get cDNA. Likewise, the study of 
melting curves and the observation of a single peak in each of 
them also allowed to confirm the amplification of a single 
amplicon for each gene under study. Of the 19 genes under 
study, no genetic expression was observed for 3 of them in 
both passages: CD34, CD45 and AdipoQ. e absence of 
CD34 and CD45 markers is considered a minimum criteria 
for the characterization of cells as MSCs [15]. e absence of 
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Figure 10:  Normalized concentration of each biomarker in the 
conditioned medium of OM-MSCs (mean ± SEM).
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these cells for neurogenic differentiation, also herein verified 
with the neurogenic differentiation protocol. It is important 
to note that, a higher percentage of GFAP-labeled cells was 
identified in OM-MSCs when compared with other undiffer-
entiated MSCs, at identical passage [108]. is might be 
related to the niche where the OM-MSCs were collected since 
the OM is naturally rich in neuroregenerative activity, which 
may turn these cells more predisposed for neurogenic differ-
entiation. CD31 is an endothelial adhesion molecule associ-
ated with endothelial and hematopoietic cells, thus its absence 
of expression in OM-MSCs is expected [109]. AE1/AE3 are 
cytokeratins related to the cytoskeleton present in almost all 
epithelia and are also useful for identifying and differentiating 
epithelial tumors [110]. Lack of expression of both CD31 and 
AE1/AE3 markers eliminates an endothelial and epithelial 
nature respectively, for OM-MSCs. In summary, immuno-
histochemical analysis reinforced the mesenchymal origin of 
OM-MSCs and confirms the tendency of these cells for neural 
differentiation.
e CM of MSCs is the set of substances extracted from 
the medium in which the MSCs are cultured and contain a 
high number of soluble factors such as cytokines, chemokines, 
immunomodulatory molecules, and growth factors with 
potential regenerative effect [111, 112]. e majority of these 
secreted factors found in MSC derived cell-free secretome 
demonstrate properties and effects identical to those described 
in the MSCs themselves, related to processes of intercellular 
communication, cell signaling, differentiation, and cell adhe-
sion, and include elements such as extra and intracellular 
matrix proteins, inflammation-related cytokines, chemokines, 
and angiogenic factors [113]. e proregenerative effects of 
MSC secretoma have been observed in several tissues and 
involve actions of modulation of the immune system, inhibi-
tion of cell death and fibrosis, stimulation of vascularization, 
promotion of tissue remodeling, and cell recruitment [114]. 
In the present study, several biomarkers were investigated and 
their concentration in the CM aer 48 h of OM-MSCs condi-
tioning was measured. e biomarkers under study are 
grouped into immunomodulatory and immunosuppressive 
factors (IFN-γ and TNF-α), chemokines (MCP-1), growth 
factors (VGEF), and interleukins (IL). All biomarkers were 
identified in the CM although with different concentrations. 
e relatively low concentrations of some of these biomarkers 
should not be surprising and does not necessarily affect their 
therapeutic efficacy when applied in vivo, since the therapeutic 
concentration of these factors in a delivery system generally 
lie in significant low ranges [115]. e concentration of INF-γ 
in the CM is relatively low, and TNF-α values are higher. At 
an organic level, the presence of these factors, as well as the 
presence of infectious toxins or hypoxia environment, stimu-
late the activation of MSCs and the production of specific 
growth factors and chemokines [116]. In fact, the combination 
of IFN-γ and proinflammatory cytokines such as TNF-α not 
only stimulates MSCs to produce and secrete high levels of 
immunosuppressive factors, as well as chemokines, but also 
adhesion molecule expression and vascular cell adhesion mol-
ecule expression [117]. e cell conditioning applied over 48 
h seems to have been enough to stimulate the release of factors 
not generally produced by MSCs such as TNF-α and IFN-γ, 
e cytogenetic evaluation of OM-MSCs allowed the iden-
tification of chromosomal stability, with a high percentage of 
normal karyotypes at all passages. is percentage, however, 
is lower in higher passages. Similarly, whereas in passages P5 
and P8 the mitotic index (i.e., the number of cells in mitosis 
in relation to the total number of cells analyzed) is normal, for 
passage P11 it decreased. In all passages the cells were analyzed 
aer reaching a confluence of 70–80%, a value that was 
observed more quickly in the lower passages. is means that 
in passage P11 a lower mitotic activity is observed for the same 
level of confluence. e lower mitotic index for passage P11 
corroborates the results observed in the remaining tests, where 
some morphological alterations, poorer cellular vitality, a 
lower number of cells in the stationary phase and lower cell 
viability were observed for higher passages, indicative of senes-
cence phenomena.
Vimentin is a widely expressed and highly conserved 
57-kD protein that constitutes type III intermediate filaments 
and is constitutively expressed in mesenchymal cells, being 
important in their development, integrity, and maintenance 
[93], and modifications in these intermediate filaments can 
lead to morphological and functional changes [94, 95]. 
Vimentin is oen identified on the surface and intracellular 
filament of MSCs and different tissues, namely the OM [96] 
and on olfactory receptor neurons which continue to express 
this marker unlike other postmitotic neurons that cease 
vimentin expression as nerve development progresses [97]. 
Having been previously identified in mice OM-MSCs [45] 
and considering its expression in cells derived from the neu-
ral crest [98], vimentin can therefore be used as a MSC 
marker on the OM. In addition, c-Kit is a type-III receptor 
tyrosine kinase that transduces cell signaling events by bind-
ing to its ligand, stem cell factor, and regulates cell prolifer-
ation, differentiation, chemotaxis, adhesion, and apoptosis 
[99]. us, it is possible to identify c-Kit immunoexpression 
in cell populations of mesenchymal origin [100] and MSCs 
[101, 102], and this marker is also expressed in the embryonic 
olfactory mucosa and olfactory epithelial progenitor cells, 
which are necessary for the maintenance of this neuroepi-
thelium and which contribute to olfactory neurogenesis 
[103]. As such, both vimentin and c-Kit can be considered 
as useful markers for MSC identification on the OM, and 
their detection in this current OM-MSCs isolated population 
corroborates its histogenesis and further classification. About 
5% of OM-MSCs stained positively for synaptophysin and 
>80% strongly labeled with GFAP. Synaptophysin is an anti-
gen related to the synaptic vesicles of neuroendocrine tissues, 
appearing in the rat’s olfactory system at OM’s olfactory neu-
rons [96] and also in olfactory bulb’s glomeruli [104]. GFAP 
is a fibrillary protein characteristic of glial cells and whose 
expression is characteristic in cells of the nervous system 
[105]. GFAP was already identified in OM-MSCs [19] and in 
MSCs subject to neurogenic differentiation [106, 107]. e 
spontaneous expression of neural markers by MSCs in their 
undifferentiated state has already been showed for different 
cell types, and is considered by some authors as an evidence 
of the MSC predisposition to differentiate into a neurogenic 
line [108]. Positive staining of undifferentiated OM-MSCs 
with synaptophysin and GFAP evidences the propensity of 
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trigger and stimulate neighboring cells to produce and secrete 
the same factors, greatly altering the CM and the secretome 
in question [133]. e major immunomodulatory agents are 
the inflammatory cytokines [135], growth factors used as a 
supplement in the culture medium [136], and also the reduced 
oxygen tension [137].
5. Conclusion and Further Directions
OM-MSCs have recently become a promise in regenerative med-
icine because of their peripheral location that makes them easy 
to collect, isolate, and expand in culture and because of their 
biological characteristics already established. With the method-
ologies applied in the present work it was possible to establish a 
protocol for isolating, culturing, freezing, and thawing the 
OM-MSCs without altering their morphological or behavioral 
characteristics in culture. Sequentially, a biological characteri-
zation was performed, allowing to identify a normal karyotype, 
several genes characteristic of MSCs and differentiations, ability 
for tridifferentiation and neurogenic differentiation and specific 
surface markers. e stemness characteristics of the OM-MSCs 
were also recognized, allowing to establish these cells as adequate 
to be applied therapeutically in future works.
Cell therapies are established as a therapeutic promise, but 
different obstacles related to their safe use, standardization of 
processes, and mechanisms of cell delivery into injured tissues 
are promoting increased attention to the therapeutic effects of 
MSCS’ paracrine secretory factors. e study of the OM-MSCs’ 
CM allowed the identification and quantification of different 
biomarkers related to immunomodulation capacity, creating 
the possibility of using the secretome of these cells in future 
regenerative therapies.
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which in turn stimulated the OM-MSCs to produce growth 
factors (VEGF) and chemokines (MCP-1). VEGF, besides its 
functions as an endothelial growth factor, plays important 
roles in the survival of MSCs in extreme organic conditions 
[118, 119]. e environmental conditions experienced by cells 
during conditioning may also be an important element in the 
production and secretion of provasculogenic factors such as 
VEGF by MSCs [120]. MCP-1, in turn, acts as a potent che-
moattractant that stimulates the recruitment and proliferation 
of MSCs and fibroblasts [121], and its presence in the 
secretome has already been reported in other OM-MSCs 
[113]. Taken together, the production of chemokines and 
growth factors by OM-MSCs subjected to conditioning has as 
main objective to stimulate cell recruitment, migration and to 
guarantee cell proliferation and survival under extreme envi-
ronmental conditions caused by the conditioning process. IL-6 
is secreted by MSCs and was initially thought to play proin-
flammatory functions. Recently, its suppressive action in the 
activity of T cells and in the control of local inflammation has 
been identified, thus performing an immunoregulatory func-
tion [122, 123]. erefore, IL-6 plays an immunosuppressive 
action and may play an important role in avoiding organic 
rejection during allogeneic implantation of MSCs [124]. e 
production of this interleukin by OM-MSCs can be an indi-
cator of the safety on the use of these cells in a therapeutic way, 
because of its immunosuppressive effect and help in avoiding 
the organic rejections to the implanted cells. IL-4 plays an 
important anti-inflammatory role and has an inhibitory effect 
on the production of TNF-α [125], which may explain the 
similar concentrations of these two factors. IL-18 is a proin-
flammatory cytokine related to the induction of inflammation 
and cell death and is thought to have inhibitory effects on cell 
proliferation and apoptosis phenomena [126, 127]. Despite 
this, some studies have shown the beneficial effects of these 
interleukins, for example, on suppressing breast cancer cells 
in vitro [128] and intracranial gliomas [129], playing an anti-
tumor effect by stimulating the activity of natural killer cells, 
reducing tumorigenesis, inducing tumor cell apoptosis, and 
inhibiting tumor angiogenesis [130]. Regardless the clarifica-
tion of its effects, the identification of this interleukins in CM 
evidences its involvement in the immunomodulatory response 
of MSCs. Unexpected is the relatively high concentrations of 
IL-2 in the CM of OM-MSCs. MSCs can control the produc-
tion and secretion of IL-2 and T cells IL-2 response through 
the secretion of IL-10 [131, 132]. It is possible that the hostile 
environment triggered by the conditioning of OM-MSCs over 
48 h may be enough to induce a proinflammatory response 
and production of IL-2, which would also explain the produc-
tion and secretion, although to a lesser extent, of other bio-
markers such as TNF-α, IFN-γ and IL-18. Despite the several 
studies already carried out, there seems to be no consensus 
regarding the components that must be found in the MSC 
secretome [133], which can be affected by aspects such as the 
assay used to obtain the CM, the niche of the MSCs, the con-
ditioning period, and the number of passages of the cells used 
to obtain it [134]. Since OM-MSCs are sensitive to the envi-
ronment in which they are found and alter their secretion 
profile according to signaling factors and surrounding envi-
ronment, changes in some cells within the culture can rapidly 
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